Show simple item record

dc.contributor.authorMiura, K
dc.contributor.authorVail, A
dc.contributor.authorChambers, D
dc.contributor.authorHopkins, PM
dc.contributor.authorFerguson, L
dc.contributor.authorGrant, M
dc.contributor.authorRhodes, LE
dc.contributor.authorGreen, Adèle C
dc.date.accessioned2018-12-05T10:35:50Z
dc.date.available2018-12-05T10:35:50Z
dc.date.issued2018en
dc.identifier.citationMiura K, Vail A, Chambers D, Hopkins PM, Ferguson L, Grant M, et al. Omega-3 fatty acid supplement skin cancer prophylaxis in lung transplant recipients: A randomized, controlled pilot trial. The Journal of Heart and Lung Transplantation [Internet]. 2018 Sep.en
dc.identifier.pmid30352778en
dc.identifier.doi10.1016/j.healun.2018.09.009en
dc.identifier.urihttp://hdl.handle.net/10541/621365
dc.description.abstractBACKGROUND: Lung transplant recipients (LTRs) are at very high risk of skin cancer. Omega-3 fatty acids (FAs) are anti-inflammatory and immune-modulating and could potentially reduce this risk. We assessed the feasibility of omega-3 FA supplementation to reduce skin cancer among these patients. METHODS: LTRs aged 18+ years, at least 1 year post-transplant, were recruited from the outpatient clinic of The Prince Charles Hospital, Brisbane. Participants were randomly allocated to 4-times-daily supplements containing either omega-3 FA (3.36 eicosapentaenoic acid [EPA]?+?docosahexaenoic acid) or placebo (4 g olive oil) for 12 months. Primary outcomes were rates of recruitment, retention, adherence (assessed by plasma omega-3 FA), and safety. Secondary outcomes were incident skin cancers. RESULTS: Among 106 eligible lung transplant recipients, 49 consented to take part (46%) with 25 allocated to omega-3 FA and 24 to placebo supplements. Of these, 22 (88%) and 20 (83%), respectively, completed the trial. After 12 months, median plasma EPA increased substantially in the intervention group (125.0 to 340.0 �mol/L), but not the placebo group (98.0 to 134.5 �mol/L). In the intervention group, 6 patients developed skin cancers compared with 11 in the placebo group, giving an odds ratio (95% confidence interval) of 0.34 (0.09 to 1.32). There were no serious, active intervention-related adverse events. CONCLUSIONS: This pilot trial among LTRs showed acceptable recruitment and high retention and adherence. We demonstrated a signal for reduction of new skin cancer cases in those taking omega-3 FA supplements, which supports the notion that a larger, more definitive trial is warranted.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.healun.2018.09.009en
dc.titleOmega-3 fatty acid supplement skin cancer prophylaxis in lung transplant recipients: A randomized, controlled pilot trialen
dc.typeArticleen
dc.contributor.departmentCancer and Population Studies Group, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australiaen
dc.identifier.journalJ Heart Lung Transplanten
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record